Rituximab for adolescents with haemophilia and high titre inhibitors

Haemophilia

Volumn 12, Issue 3, 2006, Pages 218-222

  Fox, R A ^a   Neufeld, E J ^a,b   Bennett, Carolyn M ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Haemophilia; Immune tolerance; Inhibitors; Paediatrics; Rituximab

Indexed keywords

ALLOANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; NEUTRALIZING ANTIBODY; ONDANSETRON; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RITUXIMAB; STEROID;

ADOLESCENT; ANTIBODY TITER; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOLOGICAL TOLERANCE; MALE; NAUSEA; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADOLESCENT; ANTIBODIES, MONOCLONAL; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMOPHILIA B; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC FACTORS; MALE; TREATMENT OUTCOME;

EID: 33645980622     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01215.x     Document Type: Article

References (26)

1. Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
2. Sallah S. Inhibitors to clotting factors. Ann Hematol 1997; 75: 1-7.
3. Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors: A systematic review. Haemophilia 2003; 9: 436-63.
4. Bennett CM, Rogers ZR, Kinnamon DD et al. Prospective phase I/II study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2005 [Epub ahead of print]
5. Wang J, Wiley JM, Luddy R, Greenberg J, Feuerstein MA, Bussel JB. Chronic immune thrombocytopenic purpura in children: Assessment of rituximab treatment. J Pediatr 2005; 146: 217-21.
6. Zaja F, Vianelli N, Sperotto A et al. B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 2003; 88: 538-46.
7. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98: 952-7.
8. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001; 358: 1511-3.
9. Wakim M, Shah A, Arndt PA et al. Successful anti-CD20 monoclonal antibody treatment of severe autoimmune hemolytic anemia due to warm reactive IgM autoantibody in a child with common variable immunodeficiency. Am J Hematol 2004; 76: 152-5.
10. Binstadt BA, Caldas AM, Turvey SE et al. Rituximab therapy for multisystem autoimmune diseases in pediatric patients. J Pediatr 2003; 143: 598-604.
11. Decesare T, Kett DH, Huang HS et al. Successful outcome of Rituxan therapy for spontaneously acquired high titer refractory factor VIII inhibitor. Blood 2002; 100: 105B-105B.
12. Fischer KG, Deschler B, Lubbert M. Acquired high-titer factor VIII inhibitor: Fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses. Blood 2003; 101: 3753-4 (Author reply: 4-5).
13. Kain S, Copeland TS, Leahy MF. Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab). Br J Haematol 2002; 119: 578.
14. Karwal MW, Schlueter AJ, Zenk DW, Davis RT. Treatment of acquired factor VIII deficiency with rituximab. Blood 2001; 98: 533A-533A.
15. Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103: 4424-8.
16. Tamponi G, Schinco P, Borchiellini A, Valpreda A, Pollio B, Boccadoro M. Acquired Factor VIII deficiency: Rapid and complete remission after immunosuppressive therapy with high dose cyclophosphamide and rituximab. Blood 2002; 100: 101B-101B.
17. Wiestner A, Cho HJ, Asch AS et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002; 100: 3426-8.
18. Nilsson IM, Berntorp E, Zettervall O. Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies. Proc Natl Acad Sci USA 1986; 83: 9169-73.
19. Dharnidharka VR, Takemoto C, Ewenstein BM, Rosen S, Harris HW. Membranous glomerulonephritis and nephrosis post factor IX infusions in hemophilia B. Pediatr Nephrol 1998; 12: 654-7.
20. Wiestner A, Weksler BB, Schechter GP. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2003; 101: 3754-5.
21. Escobar M, Kempton C, Ma A. Successful treatment of an autoantibody in congenital hemophilia with rituximab. Blood 2002; 100: 109B-109B.
22. Medeiros BC, Geraghty S, Stabler S. Improved response to immune tolerance therapy for factor VIII inhibitor after rituximab therapy. Blood 2002; 100: 3890.
23. Linde R, Ettingshausen CE, Voigt B, Klingebiel T, Kreuz W. First successful inhibitor elimination with a new protocol in a high responding hemophilia A patient after failure of various immune tolerance induction regimens. Blood 2001; 98: 534A-534A.
24. Mathias M, Khair K, Hann I, Liesner R. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia. Br J Haematol 2004; 125: 366-8.
25. Carcao M, St Louis J, Poon MC et al. Rituximab for congenital haemophiliacs with inhibitors: A Canadian experience. Haemophilia 2006; 12: 7-18.
26. Curtin J, Mista A, Teo J, Webster B, Lammi AT. Use of rituximab as an alternative strategy for the management of difficult high titre inhibiters in children with hemophilia. Haemophilia 2004; 10: 57.